DK259387D0 - Steroide forbindelser, der er virksomme mod kraeft og obesitet - Google Patents

Steroide forbindelser, der er virksomme mod kraeft og obesitet

Info

Publication number
DK259387D0
DK259387D0 DK259387A DK259387A DK259387D0 DK 259387 D0 DK259387 D0 DK 259387D0 DK 259387 A DK259387 A DK 259387A DK 259387 A DK259387 A DK 259387A DK 259387 D0 DK259387 D0 DK 259387D0
Authority
DK
Denmark
Prior art keywords
agent
compound
effective power
formula
compounds effective
Prior art date
Application number
DK259387A
Other languages
English (en)
Other versions
DK173168B1 (da
DK259387A (da
Inventor
Arthur G Schwartz
Marvin Louis Lewbart
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of DK259387D0 publication Critical patent/DK259387D0/da
Publication of DK259387A publication Critical patent/DK259387A/da
Application granted granted Critical
Publication of DK173168B1 publication Critical patent/DK173168B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK198702593A 1986-05-21 1987-05-21 5alfa-androsten-17-oner og 5alfa-androstan-17-oner, der er virksomme mod kræft og obesitet, samt terapeutisk middel der ind DK173168B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86711286A 1986-05-21 1986-05-21
US86711286 1986-05-21

Publications (3)

Publication Number Publication Date
DK259387D0 true DK259387D0 (da) 1987-05-21
DK259387A DK259387A (da) 1987-11-22
DK173168B1 DK173168B1 (da) 2000-02-28

Family

ID=25349110

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198702593A DK173168B1 (da) 1986-05-21 1987-05-21 5alfa-androsten-17-oner og 5alfa-androstan-17-oner, der er virksomme mod kræft og obesitet, samt terapeutisk middel der ind

Country Status (12)

Country Link
EP (1) EP0246650B1 (da)
JP (1) JP2566574B2 (da)
AT (1) ATE71107T1 (da)
AU (1) AU601184B2 (da)
CA (1) CA1329195C (da)
DE (1) DE3775617D1 (da)
DK (1) DK173168B1 (da)
ES (1) ES2039373T3 (da)
GR (1) GR3003769T3 (da)
IE (1) IE60027B1 (da)
NO (1) NO173278C (da)
PT (1) PT84911B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424463A (en) * 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5585371A (en) * 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
JP2973031B2 (ja) * 1990-08-29 1999-11-08 ヒューマネティックス コーポレーション 減量を促進するための置換δ５−アントロステンを含む医薬
JPH0684398B2 (ja) * 1990-08-31 1994-10-26 雪印乳業株式会社 新規なアンドロステン誘導体及びそれを用いる６‐アルキルカルボニルオキシ‐１４α‐ヒドロキシ‐アンドロスト‐４，６‐ジエン‐３，１７‐ジオンの製造法
CA2424581A1 (en) * 2000-10-06 2002-04-11 Aeson Therapeutics Inc. Compounds useful for treating hypertriglyceridemia
JP2005529141A (ja) * 2002-05-01 2005-09-29 アーサー シュワルツ、 ７−ヒドロキシ−１６α−フルオロ−５−アンドロステン−１７−オン類および７−ヒドロキシ−１６α−フルオロ−５−アンドロスタン−１７−オン類およびそれらの誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6069096A (ja) * 1983-08-02 1985-04-19 リサ−チ・コ−ポレイシヨン 新規ステロイド
GR862043B (en) * 1985-08-02 1986-12-24 Research Corp Steroids useful as anti-cancer anti-obesity anti-hyperglycemic anti-autoimmune and anti-hypercholesterolemic agents
JP2920854B2 (ja) * 1991-08-01 1999-07-19 富士通株式会社 ビィアホール構造及びその形成方法

Also Published As

Publication number Publication date
ATE71107T1 (de) 1992-01-15
JPS62283993A (ja) 1987-12-09
GR3003769T3 (da) 1993-03-16
IE60027B1 (en) 1994-05-18
DK173168B1 (da) 2000-02-28
IE871312L (en) 1987-11-21
NO173278C (no) 1993-12-01
PT84911B (pt) 1990-02-08
AU601184B2 (en) 1990-09-06
NO872115L (no) 1987-11-23
DK259387A (da) 1987-11-22
NO173278B (no) 1993-08-16
AU7329687A (en) 1987-11-26
ES2039373T3 (es) 1993-10-01
DE3775617D1 (de) 1992-02-13
EP0246650A1 (en) 1987-11-25
NO872115D0 (no) 1987-05-20
PT84911A (en) 1987-06-01
JP2566574B2 (ja) 1996-12-25
CA1329195C (en) 1994-05-03
EP0246650B1 (en) 1992-01-02

Similar Documents

Publication Publication Date Title
ES8706717A1 (es) Metodo de preparar esteroides
ES503768A0 (es) Procedimiento de preparacion de derivados de 1-fenil-1-hi- droxi-etilamina
NO175617C (no) Fremgangsmåte ved fremstilling av blandinger som omfatter vandig etanol, for ökning av transdermal ström
DE69015736T2 (de) 7-Keto- und 7-Hydroxy-androsta-3,5-dien-3-carbonsäure Derivate.
ATE109770T1 (de) Derivate der coffeinsäure und pharmazeutische zusammensetzungen, die sie enthalten.
DK259387D0 (da) Steroide forbindelser, der er virksomme mod kraeft og obesitet
GR3007460T3 (da)
ATE41146T1 (de) Irreversible dopamin-b-hydroxylase-inhibitoren.
NZ233704A (en) Dehydrocholecalciferol derivatives, pharmaceutical compositions thereof
EP0270046A3 (en) Pharmaceutical composition for treatment of cataract
AU640161B2 (en) 3-substituted nitro-steroid derivatives as 5-alpha-reductase inhibitors
NZ213780A (en) Diphenylmethylimine derivatives and pharmaceutical compositions
ZA882775B (en) Pharmaceutical use of organic compounds

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK